Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results
Summary
The kidney disorder doesn’t have any FDA-approved therapies, Retrophin says, but several drugs are currently used off-label to treat it, including steroids, immune system suppressants, and diuretics.Patients who received sparsentan had a 44.8 percent reduction in a symptom of the disease that’s associated with a breakdown of normal kidney function, according to the initial trial results.The results exceeded expectations, according to a note from analysts at Leerink Partners, who said the drug has a 75 percent chance to earn FDA approval.Retrophin’s involvement with sparsentan began with Shkreli, the company’s former CEO, who has since been characterized as an archetype of pharmaceutical industry greed rather than innovation.After leaving Retrophin, Shkreli founded a new biotech, Turing Pharmaceuticals where he doubled down: He raised the price of another drug, Daraprim, used to treat parasitic infections that often afflict people with HIV.
Classifications
AskAI Classifications
LabelsLinked Companies
